The global multiple sclerosis therapies market size reached USD 27.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 38.8 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033.

IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple sclerosis therapies market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on drug, drug type, route of administration and distribution channel.

The global multiple sclerosis therapeutic market size exceeded USD 26.53 billion in 2024 and is projected to expand at a CAGR of more than 4.9%, crossing USD 49.41 billion by 2037. North America industry is poised to account for largest revenue share of 45.7% by 2037, owing to well-developed healthcare facilities in the region.

The size and share of the market is categorized based on Type (Drug Treatment, Physical Therapy) and Application (Hospital, Clinic, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The Multiple Sclerosis Therapeutic Market is projected to reach $27.39 billion by 2033, exhibiting a CAGR of 5.9% from 2025 to 2033. Key drivers fueling market growth include the increasing prevalence of multiple sclerosis, rising healthcare expenditure, and the introduction of innovative therapies. The demand for immunosuppressants and injectable medications is expected to remain high due to their effectiveness in managing disease progression. The market is segmented based on drug class, route of administration, distribution channel, and region. North America held the largest market share in 2025, followed by Europe and Asia Pacific. The key players operating in this market include Teva Pharmaceutical Industries Ltd., Pfizer Inc., Biogen, Bayer AG, Sanofi, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Merck & Co., Inc., Takeda Pharmaceutical Company Limited., and Horizon Therapeutics plc. Recent developments include: In February 2024, Roche Pharma India announced the launch of Ocrevus for the treatment of MS. It is expected to cater to the requirements of patients suffering with MS in India. Ocrevus is one of its leading products and is available in more than 100 countries and in India it is approved for primary progressive & relapsing forms of MS. , In February 2024, Neuraxpharm Group announced the launch of BRIUMVI in Europe to treat adult patients suffering with relapsing MS. , In August 2023, the U.S. Food and Drug Administration (USFDA) approved Tyruko. Tyruko is the first biosimilar of Tysabri injection for treating adults suffering with relapsing form of MS. It is approved to treat relapsing-remitting disease, active secondary progressive disease and clinically isolated syndrome. .

The global multiple sclerosis drug market size is projected to grow from USD 25.07 billion to USD 42.07 billion, demonstrating a CAGR of over 4.2% during the forecast timeline, between 2025 and 2037. North America industry is anticipated to hold largest share by 2037, impelled by rising burden of multiple sclerosis among the population and a higher probability of women getting multiple sclerosis in the region.

The market size of the Stem Cell Therapy For Multiple Sclerosis Market is categorized based on Type (Intravenous, Intracerebroventricular) and Application (Relapsing-Remitting Multiple Sclerosis (RRMS), Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Progressive Relapsing Multiple Sclerosis (PRMS)) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

This report provides insights into the market size and forecasts the value of the market, expressed in USD million, across these defined segments.

The U.S. Multiple Sclerosis Drugs Market size was valued at USD 9.86 USD Billion in 2023 and is projected to reach USD 14.73 USD Billion by 2032, exhibiting a CAGR of 5.9 % during the forecast period. The United States Multiple Sclerosis (MS) Drugs market includes the process of making and delivering drugs used for multiple sclerosis treatment, which is a chronic disease affecting the central nervous system. One group of such drugs is the disease-modifying therapies (DMTs) which also encompass immunosuppressant and symptomatic treatments whose objective is to dampen the unpleasant effects of MS and hinder the progression of the disease. Applications can be found in hospitals, neurologists clinics, and specialty pharmacies among others. The main trends in the market are the continued growth of novel oral and biologic therapies; the increasing emphasis on individualized medicine; and the progress in biotechnology resulting in more efficient treatments. Moreover, the research and investment in novel treatment methods to strengthen treatment outcomes and quality of life is also a growing trend. Key drivers for this market are: Growing Patient Population to Fuel Demand for Effective Therapeutics. Potential restraints include: Limitations Associated with Diagnosis and Treatment Processes to Limit Market Growth . Notable trends are: Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.

The size of the Multiple Sclerosis Drugs and Treatment market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 3.87% during the forecast period.Multiple Sclerosis is a central nervous system auto immune disease that affects the central nervous system, which involves the brain and spinal cord. In this disease, the immune system attacks the myelin sheath that protects nerve fibers, leading to inflammation and damage. This would therefore disrupt communication between the brain and the rest of the body, which can occur through a wide range of symptoms, such as impairment in vision, muscle weakness, fatigue, and cognitive problems.MS drugs and treatments control the progression of the disease and remove the symptoms of MS. Various categories of drugs have been designed that target specific areas of the disease. Some are categorized as DMTs, or disease-modifying therapies, where the action is immunosuppressive, thus reducing the severity and frequency of relapse attacks. The others include corticosteroids to treat acute attacks of the disease and reduce inflammation.Recently, major breakthroughs have occurred in treatment development for MS. More and more targeted and specific new oral drugs and infusion therapies that are more effective on the disease are being discovered. Other novel approaches include stem cell transplantation and gene therapy. Because of this, the market for MS drugs and treatment is constantly evolving as these are continuously researched and developed to improve patient outcomes and quality of life. Recent developments include: October 2023: Bristol Myers Squibb presented Zeposia's (ozanimod) data on long-term disease progression and cognition in patients with relapsing forms of multiple sclerosis (MS). 76% of patients treated with Zeposia for relapsing multiple sclerosis (RMS) were free of six-month confirmed disability progression (CDP)., September 2023: Sandoz received the European Commission (EC) marketing authorization for biosimilar Tyruko (natalizumab) for multiple sclerosis. The US FDA approved the same product in August 2023.. Key drivers for this market are: Rising Cases of Multiple Sclerosis across the World, Growing Focus of Companies on Pipeline Products for MS. Potential restraints include: Side Effects Associated with the Medication, High Cost of the Drugs. Notable trends are: The Oral Route of Administration is Expected to Witness Rapid Growth in Over the Forecast Period.

The global Multiple Sclerosis Therapeutics Market is expected to reach USD 33.57 billion by 2032 and grow at a CAGR of 5.4%.

Asia Pacific Multiple Sclerosis Drugs Treatment market USD 4954.55 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031. rising disease awareness, improving healthcare infrastructure is expected to aid the sales to USD 9451.1 million by 2031

The size and share of the market is categorized based on Type (COG-133, GZ-402668, Inebilizumab, VCE-0032, Others) and Application (Clinic, Hopital, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The market offers a comprehensive array of therapeutic interventions, encompassing immunomodulatory and immunosuppressive agents. These therapies are administered via multiple routes, including injectables, oral medications, and specialized delivery systems. Cutting-edge diagnostic modalities, such as Magnetic Resonance Imaging (MRI) scans, have enhanced the precision of MS diagnosis, while other techniques like Simple Electrical Stimulation Tests and Lumbar Puncture provide valuable insights into disease activity. Recent developments include: March 2021:The Janssen Pharmaceutical Companies of Johnson & Johnson’s PONVORY for treating adults with relapsing forms of multiple sclerosis was approved by the US Food and Drug Administration (FDA).. Notable trends are: Significant R&D Investment to boost the market growth.

Global Multiple Sclerosis Drugs Market to hit USD 47.97B by 2029 growing at 11.1% CAGR. Explore trends, drivers, and competition for strategic insights with The Business Research Company.

North America Multiple Sclerosis Drugs Treatment market size will be USD 8616.60 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. North America has emerged as a prominent participant, and its sales revenue is estimated to reach USD 14250.5 Million by 2031. This growth is mainly attributed to the region's advanced healthcare infrastructure.

Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch to the oral disease-modifying therapies (DMTs), lessening the stronghold of the established injectable treatments. There are also several promising products in the late-stage pipeline, with a diverse range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline and marketed DMTs are seeking approval for the treatment of progressive MS, which currently represents a significant unmet need. These factors are expected to increase treatment rates throughout the 10MM resulting, driving market growth. However, this will be largely offset by brand erosion due to the emergence of biosimilars and generic small molecules. Read More

Technological advancements in the North America Multiple Sclerosis Therapeutics industry are shaping the future market landscape. The report evaluates innovation-driven growth and how emerging technologies are transforming industry practices, offering a comprehensive outlook on future opportunities and market potential.

Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch to the oral disease-modifying therapies (DMTs), lessening the stronghold of the established injectable treatments. There are also several promising products in the late-stage pipeline, with a diverse range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline and marketed DMTs are seeking approval for the treatment of progressive MS, which currently represents a significant unmet need. These factors are expected to increase treatment rates throughout the 10MM resulting, driving market growth. However, this will be largely offset by brand erosion due to the emergence of biosimilars and generic small molecules. Sales of DMT products in China were estimated to be $61.3m in 2014, making it the second smallest MS market behind India. GlobalData anticipates steep growth to occur mid-forecast resulting from the launch of the first oral DMTs in China. Currently only four DMTs are available, with mitoxantrone being used off-label for MS in China. As such, the anticipated approval of two oral agents will not only provide added convenience for patients but will increase the diversity of treatment options, leading to a notable rise in treatment rates. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Read More

Technological advancements in the North America Multiple Sclerosis Drugs Treatment industry are shaping the future market landscape. The report evaluates innovation-driven growth and how emerging technologies are transforming industry practices, offering a comprehensive outlook on future opportunities and market potential.

GlobalData has released its new Country report, “Multiple Sclerosis – China Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace. Read More

Middle East and Africa Multiple Sclerosis Drugs Treatment market will be USD 430.83 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031. The market is foreseen to reach USD 775.3 million by 2031, owing to growing awareness and improved diagnostic capabilities.